Navigation Links
Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
Date:4/16/2009

CLEVELAND, Ohio, April 16 /PRNewswire/ -- Simbionix, the world's leading developer of medical simulation systems, today announced an agreement with Johnson & Johnson LLC for distribution of Simbionix's simulators and related products.

Johnson & Johnson, LLC operates in Russia, Ukraine and CIS countries and is one of the subsidiaries of Johnson & Johnson.

Johnson & Johnson LLC will have exclusive rights to distribute Simbionix's line of advanced medical simulators in hospitals in the Russia and CIS countries.

"We are very excited to enter into this collaboration with Johnson & Johnson LLC to bring our advanced simulators into the Russian republic' hospitals, teaching facilities and interventional clinics," said Simbionix CEO Gary Zamler. "This agreement ushers in a new era of simulation-based training for Russia's medical community and we envision beneficial for the countries covered by the agreement, Johnson & Johnson LLC,and Simbionix."

"In the last year, Simbionix has increased its distribution channels and its exposure to the international market, "explains Mr. Doron Zilberman, Simbionix's VP of International Sales. "We see Russia as one of the leading markets in the emerging medical world; this agreement is an additional step of our on going success in the international market ..."

About Simbionix

Simbionix is a global leader in medical simulation technology. Simbionix mission is to provide state of the art, computer-assisted metrics-based surgical simulation systems, and set the standard for minimally invasive surgical training and performance.

Simbionix products provide medical experts with hands-on training in a comprehensive array of MIS procedures, including; GI Endoscopy, Endourology, percutaneous access, advanced laparoscopic procedures and Endovascular procedures. Visit http://www.simbionix.com

    Contact:

    Inbal Mazor
    VP Marketing
    Simbionix
    mailto:inbal@simbionix.com
    Tel: +972-8-9211177 ext. 222
   http://www.simbionix.com


'/>"/>
SOURCE Simbionix Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
2. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
3. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
4. Premier Research Announces Milestone Investigational New Drug Application
5. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
6. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
9. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
10. Schering-Plough Announces Results of the Early ACS Trial
11. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):